Assenagon Asset Management S.A. Sells 43,668 Shares of Charles River Laboratories International, Inc. $CRL

Assenagon Asset Management S.A. cut its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 66.3% in the first quarter, HoldingsChannel reports. The firm owned 22,211 shares of the medical research company’s stock after selling 43,668 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Charles River Laboratories International were worth $3,831,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. SG Americas Securities LLC increased its holdings in shares of Charles River Laboratories International by 2.4% in the 1st quarter. SG Americas Securities LLC now owns 186,173 shares of the medical research company’s stock worth $32,115,000 after buying an additional 4,395 shares during the last quarter. Purpose Unlimited Inc. bought a new position in shares of Charles River Laboratories International in the 4th quarter valued at about $698,000. Rockefeller Capital Management L.P. lifted its holdings in shares of Charles River Laboratories International by 30.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,750 shares of the medical research company’s stock valued at $349,000 after acquiring an additional 404 shares during the last quarter. Eos Management L.P. purchased a new position in Charles River Laboratories International in the fourth quarter worth about $839,000. Finally, Corient Private Wealth LLC grew its position in Charles River Laboratories International by 68.5% in the fourth quarter. Corient Private Wealth LLC now owns 17,628 shares of the medical research company’s stock worth $3,516,000 after acquiring an additional 7,166 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Stock Up 4.2%

Shares of CRL opened at $224.84 on Tuesday. The firm has a fifty day moving average price of $177.94 and a 200-day moving average price of $183.61. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90. The firm has a market capitalization of $10.83 billion, a P/E ratio of -59.80, a P/E/G ratio of 2.46 and a beta of 1.46. Charles River Laboratories International, Inc. has a 12-month low of $144.26 and a 12-month high of $228.88.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, topping the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company had revenue of $995.83 million for the quarter, compared to the consensus estimate of $977.46 million. During the same quarter last year, the firm posted $2.34 EPS. The firm’s revenue was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Equities research analysts expect that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on CRL shares. Royal Bank Of Canada initiated coverage on Charles River Laboratories International in a research report on Tuesday, April 14th. They set an “outperform” rating and a $215.00 price objective on the stock. Evercore reiterated an “outperform” rating and issued a $220.00 target price on shares of Charles River Laboratories International in a report on Friday, May 8th. Barclays boosted their target price on Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Weiss Ratings lowered Charles River Laboratories International from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 16th. Finally, Mizuho set a $192.00 price target on Charles River Laboratories International in a research report on Friday, May 8th. Twelve analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $211.00.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.